Cargando…
Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
PURPOSE: We presented retrospective analysis of up to five polymorphisms in TS, MTHFR and ERCC1 genes as molecular predictive markers for homogeneous Caucasian, non-squamous NSCLC patients treated with pemetrexed and platinum front-line chemotherapy. METHODS: The following polymorphisms in DNA isola...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4228108/ https://www.ncbi.nlm.nih.gov/pubmed/25028118 http://dx.doi.org/10.1007/s00432-014-1756-6 |
_version_ | 1782343917295894528 |
---|---|
author | Krawczyk, Paweł Kucharczyk, Tomasz Kowalski, Dariusz M. Powrózek, Tomasz Ramlau, Rodryg Kalinka-Warzocha, Ewa Winiarczyk, Kinga Knetki-Wróblewska, Magdalena Wojas-Krawczyk, Kamila Kałakucka, Katarzyna Dyszkiewicz, Wojciech Krzakowski, Maciej Milanowski, Janusz |
author_facet | Krawczyk, Paweł Kucharczyk, Tomasz Kowalski, Dariusz M. Powrózek, Tomasz Ramlau, Rodryg Kalinka-Warzocha, Ewa Winiarczyk, Kinga Knetki-Wróblewska, Magdalena Wojas-Krawczyk, Kamila Kałakucka, Katarzyna Dyszkiewicz, Wojciech Krzakowski, Maciej Milanowski, Janusz |
author_sort | Krawczyk, Paweł |
collection | PubMed |
description | PURPOSE: We presented retrospective analysis of up to five polymorphisms in TS, MTHFR and ERCC1 genes as molecular predictive markers for homogeneous Caucasian, non-squamous NSCLC patients treated with pemetrexed and platinum front-line chemotherapy. METHODS: The following polymorphisms in DNA isolated from 115 patients were analyzed: various number of 28-bp tandem repeats in 5′-UTR region of TS gene, single nucleotide polymorphism (SNP) within the second tandem repeat of TS gene (G>C); 6-bp deletion in 3′-UTR region of the TS (1494del6); 677C>T SNP in MTHFR; 19007C>T SNP in ERCC1. Molecular examinations’ results were correlated with disease control rate, progression-free survival (PFS) and overall survival. RESULTS: Polymorphic tandem repeat sequence (2R, 3R) in the enhancer region of TS gene and G>C SNP within the second repeat of 3R allele seem to be important for the effectiveness of platinum and pemetrexed in first-line chemotherapy. The insignificant shortening of PFS in 3R/3R homozygotes as compared to 2R/2R and 2R/3R genotypes were observed, while it was significantly shorter in patients carrying synchronous 3R allele and G nucleotide. The combined analysis of TS VNTR and MTHFR 677C>T SNP revealed shortening of PFS in synchronous carriers of 3R allele in TS and two C alleles in MTHFR. The strongest factors increased the risk of progression were poor PS, weight loss, anemia and synchronous presence of 3R allele and G nucleotide in the second repeat of 3R allele in TS. Moreover, lack of application of second-line chemotherapy, weight loss and poor performance status and above-mentioned genotype of TS gene increased risk of early mortality. CONCLUSION: The examined polymorphisms should be accounted as molecular predictor factors for pemetrexed- and platinum-based front-line chemotherapy in non-squamous NSCLC patients. |
format | Online Article Text |
id | pubmed-4228108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-42281082014-11-17 Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients Krawczyk, Paweł Kucharczyk, Tomasz Kowalski, Dariusz M. Powrózek, Tomasz Ramlau, Rodryg Kalinka-Warzocha, Ewa Winiarczyk, Kinga Knetki-Wróblewska, Magdalena Wojas-Krawczyk, Kamila Kałakucka, Katarzyna Dyszkiewicz, Wojciech Krzakowski, Maciej Milanowski, Janusz J Cancer Res Clin Oncol Original Article – Cancer Research PURPOSE: We presented retrospective analysis of up to five polymorphisms in TS, MTHFR and ERCC1 genes as molecular predictive markers for homogeneous Caucasian, non-squamous NSCLC patients treated with pemetrexed and platinum front-line chemotherapy. METHODS: The following polymorphisms in DNA isolated from 115 patients were analyzed: various number of 28-bp tandem repeats in 5′-UTR region of TS gene, single nucleotide polymorphism (SNP) within the second tandem repeat of TS gene (G>C); 6-bp deletion in 3′-UTR region of the TS (1494del6); 677C>T SNP in MTHFR; 19007C>T SNP in ERCC1. Molecular examinations’ results were correlated with disease control rate, progression-free survival (PFS) and overall survival. RESULTS: Polymorphic tandem repeat sequence (2R, 3R) in the enhancer region of TS gene and G>C SNP within the second repeat of 3R allele seem to be important for the effectiveness of platinum and pemetrexed in first-line chemotherapy. The insignificant shortening of PFS in 3R/3R homozygotes as compared to 2R/2R and 2R/3R genotypes were observed, while it was significantly shorter in patients carrying synchronous 3R allele and G nucleotide. The combined analysis of TS VNTR and MTHFR 677C>T SNP revealed shortening of PFS in synchronous carriers of 3R allele in TS and two C alleles in MTHFR. The strongest factors increased the risk of progression were poor PS, weight loss, anemia and synchronous presence of 3R allele and G nucleotide in the second repeat of 3R allele in TS. Moreover, lack of application of second-line chemotherapy, weight loss and poor performance status and above-mentioned genotype of TS gene increased risk of early mortality. CONCLUSION: The examined polymorphisms should be accounted as molecular predictor factors for pemetrexed- and platinum-based front-line chemotherapy in non-squamous NSCLC patients. Springer Berlin Heidelberg 2014-07-16 2014 /pmc/articles/PMC4228108/ /pubmed/25028118 http://dx.doi.org/10.1007/s00432-014-1756-6 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Article – Cancer Research Krawczyk, Paweł Kucharczyk, Tomasz Kowalski, Dariusz M. Powrózek, Tomasz Ramlau, Rodryg Kalinka-Warzocha, Ewa Winiarczyk, Kinga Knetki-Wróblewska, Magdalena Wojas-Krawczyk, Kamila Kałakucka, Katarzyna Dyszkiewicz, Wojciech Krzakowski, Maciej Milanowski, Janusz Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients |
title | Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients |
title_full | Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients |
title_fullStr | Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients |
title_full_unstemmed | Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients |
title_short | Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients |
title_sort | polymorphisms in ts, mthfr and ercc1 genes as predictive markers in first-line platinum and pemetrexed therapy in nsclc patients |
topic | Original Article – Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4228108/ https://www.ncbi.nlm.nih.gov/pubmed/25028118 http://dx.doi.org/10.1007/s00432-014-1756-6 |
work_keys_str_mv | AT krawczykpaweł polymorphismsintsmthfrandercc1genesaspredictivemarkersinfirstlineplatinumandpemetrexedtherapyinnsclcpatients AT kucharczyktomasz polymorphismsintsmthfrandercc1genesaspredictivemarkersinfirstlineplatinumandpemetrexedtherapyinnsclcpatients AT kowalskidariuszm polymorphismsintsmthfrandercc1genesaspredictivemarkersinfirstlineplatinumandpemetrexedtherapyinnsclcpatients AT powrozektomasz polymorphismsintsmthfrandercc1genesaspredictivemarkersinfirstlineplatinumandpemetrexedtherapyinnsclcpatients AT ramlaurodryg polymorphismsintsmthfrandercc1genesaspredictivemarkersinfirstlineplatinumandpemetrexedtherapyinnsclcpatients AT kalinkawarzochaewa polymorphismsintsmthfrandercc1genesaspredictivemarkersinfirstlineplatinumandpemetrexedtherapyinnsclcpatients AT winiarczykkinga polymorphismsintsmthfrandercc1genesaspredictivemarkersinfirstlineplatinumandpemetrexedtherapyinnsclcpatients AT knetkiwroblewskamagdalena polymorphismsintsmthfrandercc1genesaspredictivemarkersinfirstlineplatinumandpemetrexedtherapyinnsclcpatients AT wojaskrawczykkamila polymorphismsintsmthfrandercc1genesaspredictivemarkersinfirstlineplatinumandpemetrexedtherapyinnsclcpatients AT kałakuckakatarzyna polymorphismsintsmthfrandercc1genesaspredictivemarkersinfirstlineplatinumandpemetrexedtherapyinnsclcpatients AT dyszkiewiczwojciech polymorphismsintsmthfrandercc1genesaspredictivemarkersinfirstlineplatinumandpemetrexedtherapyinnsclcpatients AT krzakowskimaciej polymorphismsintsmthfrandercc1genesaspredictivemarkersinfirstlineplatinumandpemetrexedtherapyinnsclcpatients AT milanowskijanusz polymorphismsintsmthfrandercc1genesaspredictivemarkersinfirstlineplatinumandpemetrexedtherapyinnsclcpatients |